Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 587

1.

Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with HCV infection.

Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Yukimoto A, Hirooka M, Abe M, Hiasa Y.

Hepatol Res. 2018 Oct 18. doi: 10.1111/hepr.13278. [Epub ahead of print]

PMID:
30335208
2.

Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma.

Hirooka M, Ochi H, Hiraoka A, Koizumi Y, Matsuura B, Joko K, Michitaka K, Abe M, Hiasa Y.

Intern Med. 2018 Oct 17. doi: 10.2169/internalmedicine.1874-18. [Epub ahead of print]

3.

The Serum Creatinine Level might be Associated with the Onset of Impaired Fasting Glucose: A Community-based Longitudinal Cohort Health Checkup Study.

Yoshida N, Miyake T, Yamamoto S, Furukawa S, Senba H, Kanzaki S, Koizumi M, Ishihara T, Yoshida O, Hirooka M, Kumagi T, Abe M, Kitai K, Matsuura B, Hiasa Y.

Intern Med. 2018 Oct 17. doi: 10.2169/internalmedicine.0760-18. [Epub ahead of print]

4.

Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease.

Miyake T, Yoshida S, Furukawa S, Sakai T, Tada F, Senba H, Yamamoto S, Koizumi Y, Yoshida O, Hirooka M, Kumagi T, Niiya T, Miyaoka H, Masanori A, Matsuura B, Hiasa Y.

Open Med (Wars). 2018 Sep 14;13:402-409. doi: 10.1515/med-2018-0059. eCollection 2018.

5.

Prospective cohort trial to confirm the efficacy of no-touch radio frequency ablation.

Hirooka M, Hiraoka A, Ochi H, Koizumi Y, Michitaka K, Joko K, Abe M, Hiasa Y.

J Gastroenterol Hepatol. 2018 Sep 17. doi: 10.1111/jgh.14476. [Epub ahead of print]

PMID:
30225957
6.

A rare case of acute pancreatitis caused by Candida Albicans.

Tange K, Yokota T, Sunago K, Aono M, Ochi H, Takechi S, Mashiba T, Hida AI, Oshiro Y, Joko K, Kumagi T, Hiasa Y.

Clin J Gastroenterol. 2018 Aug 28. doi: 10.1007/s12328-018-0896-7. [Epub ahead of print]

PMID:
30155835
7.

Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis.

Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Itobayashi E, Shimada N, Tajiri K, Tsuji K, Ishikawa T, Ochi H, Hirooka M, Tsutsui A, Shibata H, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).

Hepatol Res. 2018 Aug 24. doi: 10.1111/hepr.13243. [Epub ahead of print]

PMID:
30144256
8.

Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).

Al Mahtab M, Akbar SMF, Aguilar JC, Guillen G, Penton E, Tuero A, Yoshida O, Hiasa Y, Onji M.

PLoS One. 2018 Aug 22;13(8):e0201236. doi: 10.1371/journal.pone.0201236. eCollection 2018.

9.

Percutaneous closure of patent foramen ovale for paradoxical embolism in acute limb ischemia.

Takafuji H, Hosokawa S, Ogura R, Hiasa Y.

Cardiovasc Interv Ther. 2018 Aug 14. doi: 10.1007/s12928-018-0542-9. [Epub ahead of print] No abstract available.

PMID:
30109674
10.

The effectiveness of dapagliflozin for sleep-disordered breathing among Japanese patients with obesity and type 2 diabetes mellitus.

Furukawa S, Miyake T, Senba H, Sakai T, Furukawa E, Yamamoto S, Niiya T, Matsuura B, Hiasa Y.

Endocr J. 2018 Sep 27;65(9):953-961. doi: 10.1507/endocrj.EJ17-0545. Epub 2018 Jul 26.

11.

Low Urine pH Is Associated with Non-alcoholic Fatty Liver Disease: A Community-based Cross-sectional Study.

Miyake T, Yoshida S, Yamamoto S, Furukawa S, Yoshida O, Kanzaki S, Senba H, Ishihara T, Koizumi M, Tokumoto Y, Hirooka M, Kumagi T, Abe M, Kitai K, Matsuura B, Hiasa Y.

Intern Med. 2018 Oct 1;57(19):2799-2805. doi: 10.2169/internalmedicine.0167-17. Epub 2018 May 18.

12.

Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method.

Tamaki N, Koizumi Y, Hirooka M, Yada N, Takada H, Nakashima O, Kudo M, Hiasa Y, Izumi N.

Hepatol Res. 2018 Sep;48(10):821-828. doi: 10.1111/hepr.13179. Epub 2018 May 18.

PMID:
29679473
13.

Validation trial for efficacy of ultrasonographic measurement method to predict ascitic volume using virtual ultrasonography.

Hirooka M, Koizumi Y, Imai Y, Yukimoto A, Watanabe T, Yoshida O, Abe M, Hiasa Y.

J Med Ultrason (2001). 2018 Oct;45(4):555-564. doi: 10.1007/s10396-018-0879-9. Epub 2018 Apr 18.

PMID:
29671146
14.

Cigarette smoking is a risk factor for the onset of fatty liver disease in nondrinkers: A longitudinal cohort study.

Okamoto M, Miyake T, Kitai K, Furukawa S, Yamamoto S, Senba H, Kanzaki S, Deguchi A, Koizumi M, Ishihara T, Miyaoka H, Yoshida O, Hirooka M, Kumagi T, Abe M, Matsuura B, Hiasa Y.

PLoS One. 2018 Apr 17;13(4):e0195147. doi: 10.1371/journal.pone.0195147. eCollection 2018.

15.

Mortality impact of post-discharge myocardial infarction size after percutaneous coronary intervention: a patient-level pooled analysis from the 4 large-scale Japanese studies.

Watanabe H, Morimoto T, Shiomi H, Yoshikawa Y, Kato T, Saito N, Shizuta S, Ono K, Yamaji K, Ando K, Kaji S, Furukawa Y, Akao M, Ishikawa T, Tamura T, Yamamoto Y, Muramatsu T, Suwa S, Nakagawa Y, Kadota K, Takatsu Y, Nishikawa H, Hiasa Y, Hayashi Y, Miyazaki S, Kimura T.

Cardiovasc Interv Ther. 2018 Mar 5. doi: 10.1007/s12928-018-0517-x. [Epub ahead of print]

PMID:
29508236
16.

Roles of protein kinase R in cancer: Potential as a therapeutic target.

Watanabe T, Imamura T, Hiasa Y.

Cancer Sci. 2018 Apr;109(4):919-925. doi: 10.1111/cas.13551. Epub 2018 Mar 23. Review.

17.

Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma.

Hirooka M, Hiraoka A, Ochi H, Kisaka Y, Joko K, Michitaka K, Hiasa Y.

AJR Am J Roentgenol. 2018 Apr;210(4):891-898. doi: 10.2214/AJR.17.18177. Epub 2018 Feb 7.

PMID:
29412017
18.

Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease.

Masugi Y, Abe T, Tsujikawa H, Effendi K, Hashiguchi A, Abe M, Imai Y, Hino K, Hige S, Kawanaka M, Yamada G, Kage M, Korenaga M, Hiasa Y, Mizokami M, Sakamoto M.

Hepatol Commun. 2017 Nov 27;2(1):58-68. doi: 10.1002/hep4.1121. eCollection 2018 Jan.

19.

Nonalcoholic fatty liver with a hepatic arterial buffer response strongly associated with future metabolic disease.

Hirooka M, Koizumi Y, Miyake T, Watanabe T, Yoshida O, Tokumoto Y, Yukimoto A, Nakamura Y, Imai Y, Abe M, Hiasa Y.

Hepatol Commun. 2017 Jul 27;1(7):623-633. doi: 10.1002/hep4.1070. eCollection 2017 Sep.

20.

Relative changes in handgrip strength and skeletal muscle volume in patients with chronic liver disease over a 2-year observation period.

Hiraoka A, Michitaka K, Izumoto H, Ueki H, Kitahata S, Aibiki T, Okudaira T, Yamago H, Miyamoto Y, Iwasaki R, Tomida H, Mori K, Miyata H, Tsubouchi E, Kishida M, Hirooka M, Abe M, Matsuura B, Ninomiya T, Hiasa Y.

Hepatol Res. 2018 Jun;48(7):502-508. doi: 10.1111/hepr.13051. Epub 2018 Feb 6.

PMID:
29314571

Supplemental Content

Loading ...
Support Center